Abstract
Summary
LPI (LP Information)' newest research report, the “Faecal Microbiota Transplant(FMT) Therapy Industry Forecast” looks at past sales and reviews total world Faecal Microbiota Transplant(FMT) Therapy sales in 2022, providing a comprehensive analysis by region and market sector of projected Faecal Microbiota Transplant(FMT) Therapy sales for 2023 through 2029. With Faecal Microbiota Transplant(FMT) Therapy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Faecal Microbiota Transplant(FMT) Therapy industry.
This Insight Report provides a comprehensive analysis of the global Faecal Microbiota Transplant(FMT) Therapy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Faecal Microbiota Transplant(FMT) Therapy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Faecal Microbiota Transplant(FMT) Therapy market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Faecal Microbiota Transplant(FMT) Therapy and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Faecal Microbiota Transplant(FMT) Therapy.
The global Faecal Microbiota Transplant(FMT) Therapy market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Faecal Microbiota Transplant(FMT) Therapy is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Faecal Microbiota Transplant(FMT) Therapy is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Faecal Microbiota Transplant(FMT) Therapy is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Faecal Microbiota Transplant(FMT) Therapy players cover Enterome Bioscience, Rebiotix, Ritter Pharmaceuticals, Finch Therapeutics, Crestovo, Maat Pharma, Seres Therapeutics, Second Genome and OpenBiome, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Faecal Microbiota Transplant(FMT) Therapy market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Oral
Enema
Segmentation by application
Clostridioides Difficile Infection(CDI)
Digestive System Disease
Nervous System Disease
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Enterome Bioscience
Rebiotix
Ritter Pharmaceuticals
Finch Therapeutics
Crestovo
Maat Pharma
Seres Therapeutics
Second Genome
OpenBiome
MicroBiome Therapeutics
This Insight Report provides a comprehensive analysis of the global Faecal Microbiota Transplant(FMT) Therapy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Faecal Microbiota Transplant(FMT) Therapy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Faecal Microbiota Transplant(FMT) Therapy market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Faecal Microbiota Transplant(FMT) Therapy and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Faecal Microbiota Transplant(FMT) Therapy.
The global Faecal Microbiota Transplant(FMT) Therapy market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Faecal Microbiota Transplant(FMT) Therapy is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Faecal Microbiota Transplant(FMT) Therapy is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Faecal Microbiota Transplant(FMT) Therapy is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Faecal Microbiota Transplant(FMT) Therapy players cover Enterome Bioscience, Rebiotix, Ritter Pharmaceuticals, Finch Therapeutics, Crestovo, Maat Pharma, Seres Therapeutics, Second Genome and OpenBiome, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Faecal Microbiota Transplant(FMT) Therapy market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Oral
Enema
Segmentation by application
Clostridioides Difficile Infection(CDI)
Digestive System Disease
Nervous System Disease
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Enterome Bioscience
Rebiotix
Ritter Pharmaceuticals
Finch Therapeutics
Crestovo
Maat Pharma
Seres Therapeutics
Second Genome
OpenBiome
MicroBiome Therapeutics
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Faecal Microbiota Transplant(FMT) Therapy Market Size 2018-2029
2.1.2 Faecal Microbiota Transplant(FMT) Therapy Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 Faecal Microbiota Transplant(FMT) Therapy Segment by Type
2.2.1 Oral
2.2.2 Enema
2.3 Faecal Microbiota Transplant(FMT) Therapy Market Size by Type
2.3.1 Faecal Microbiota Transplant(FMT) Therapy Market Size CAGR by Type (2018 VS 2022 VS 2029)
2.3.2 Global Faecal Microbiota Transplant(FMT) Therapy Market Size Market Share by Type (2018-2023)
2.4 Faecal Microbiota Transplant(FMT) Therapy Segment by Application
2.4.1 Clostridioides Difficile Infection(CDI)
2.4.2 Digestive System Disease
2.4.3 Nervous System Disease
2.4.4 Others
2.5 Faecal Microbiota Transplant(FMT) Therapy Market Size by Application
2.5.1 Faecal Microbiota Transplant(FMT) Therapy Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global Faecal Microbiota Transplant(FMT) Therapy Market Size Market Share by Application (2018-2023)
3 Faecal Microbiota Transplant(FMT) Therapy Market Size by Player
3.1 Faecal Microbiota Transplant(FMT) Therapy Market Size Market Share by Players
3.1.1 Global Faecal Microbiota Transplant(FMT) Therapy Revenue by Players (2018-2023)
3.1.2 Global Faecal Microbiota Transplant(FMT) Therapy Revenue Market Share by Players (2018-2023)
3.2 Global Faecal Microbiota Transplant(FMT) Therapy Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Faecal Microbiota Transplant(FMT) Therapy by Regions
4.1 Faecal Microbiota Transplant(FMT) Therapy Market Size by Regions (2018-2023)
4.2 Americas Faecal Microbiota Transplant(FMT) Therapy Market Size Growth (2018-2023)
4.3 APAC Faecal Microbiota Transplant(FMT) Therapy Market Size Growth (2018-2023)
4.4 Europe Faecal Microbiota Transplant(FMT) Therapy Market Size Growth (2018-2023)
4.5 Middle East & Africa Faecal Microbiota Transplant(FMT) Therapy Market Size Growth (2018-2023)
5 Americas
5.1 Americas Faecal Microbiota Transplant(FMT) Therapy Market Size by Country (2018-2023)
5.2 Americas Faecal Microbiota Transplant(FMT) Therapy Market Size by Type (2018-2023)
5.3 Americas Faecal Microbiota Transplant(FMT) Therapy Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Faecal Microbiota Transplant(FMT) Therapy Market Size by Region (2018-2023)
6.2 APAC Faecal Microbiota Transplant(FMT) Therapy Market Size by Type (2018-2023)
6.3 APAC Faecal Microbiota Transplant(FMT) Therapy Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Faecal Microbiota Transplant(FMT) Therapy by Country (2018-2023)
7.2 Europe Faecal Microbiota Transplant(FMT) Therapy Market Size by Type (2018-2023)
7.3 Europe Faecal Microbiota Transplant(FMT) Therapy Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Faecal Microbiota Transplant(FMT) Therapy by Region (2018-2023)
8.2 Middle East & Africa Faecal Microbiota Transplant(FMT) Therapy Market Size by Type (2018-2023)
8.3 Middle East & Africa Faecal Microbiota Transplant(FMT) Therapy Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Faecal Microbiota Transplant(FMT) Therapy Market Forecast
10.1 Global Faecal Microbiota Transplant(FMT) Therapy Forecast by Regions (2024-2029)
10.1.1 Global Faecal Microbiota Transplant(FMT) Therapy Forecast by Regions (2024-2029)
10.1.2 Americas Faecal Microbiota Transplant(FMT) Therapy Forecast
10.1.3 APAC Faecal Microbiota Transplant(FMT) Therapy Forecast
10.1.4 Europe Faecal Microbiota Transplant(FMT) Therapy Forecast
10.1.5 Middle East & Africa Faecal Microbiota Transplant(FMT) Therapy Forecast
10.2 Americas Faecal Microbiota Transplant(FMT) Therapy Forecast by Country (2024-2029)
10.2.1 United States Faecal Microbiota Transplant(FMT) Therapy Market Forecast
10.2.2 Canada Faecal Microbiota Transplant(FMT) Therapy Market Forecast
10.2.3 Mexico Faecal Microbiota Transplant(FMT) Therapy Market Forecast
10.2.4 Brazil Faecal Microbiota Transplant(FMT) Therapy Market Forecast
10.3 APAC Faecal Microbiota Transplant(FMT) Therapy Forecast by Region (2024-2029)
10.3.1 China Faecal Microbiota Transplant(FMT) Therapy Market Forecast
10.3.2 Japan Faecal Microbiota Transplant(FMT) Therapy Market Forecast
10.3.3 Korea Faecal Microbiota Transplant(FMT) Therapy Market Forecast
10.3.4 Southeast Asia Faecal Microbiota Transplant(FMT) Therapy Market Forecast
10.3.5 India Faecal Microbiota Transplant(FMT) Therapy Market Forecast
10.3.6 Australia Faecal Microbiota Transplant(FMT) Therapy Market Forecast
10.4 Europe Faecal Microbiota Transplant(FMT) Therapy Forecast by Country (2024-2029)
10.4.1 Germany Faecal Microbiota Transplant(FMT) Therapy Market Forecast
10.4.2 France Faecal Microbiota Transplant(FMT) Therapy Market Forecast
10.4.3 UK Faecal Microbiota Transplant(FMT) Therapy Market Forecast
10.4.4 Italy Faecal Microbiota Transplant(FMT) Therapy Market Forecast
10.4.5 Russia Faecal Microbiota Transplant(FMT) Therapy Market Forecast
10.5 Middle East & Africa Faecal Microbiota Transplant(FMT) Therapy Forecast by Region (2024-2029)
10.5.1 Egypt Faecal Microbiota Transplant(FMT) Therapy Market Forecast
10.5.2 South Africa Faecal Microbiota Transplant(FMT) Therapy Market Forecast
10.5.3 Israel Faecal Microbiota Transplant(FMT) Therapy Market Forecast
10.5.4 Turkey Faecal Microbiota Transplant(FMT) Therapy Market Forecast
10.5.5 GCC Countries Faecal Microbiota Transplant(FMT) Therapy Market Forecast
10.6 Global Faecal Microbiota Transplant(FMT) Therapy Forecast by Type (2024-2029)
10.7 Global Faecal Microbiota Transplant(FMT) Therapy Forecast by Application (2024-2029)
11 Key Players Analysis
11.1 Enterome Bioscience
11.1.1 Enterome Bioscience Company Information
11.1.2 Enterome Bioscience Faecal Microbiota Transplant(FMT) Therapy Product Offered
11.1.3 Enterome Bioscience Faecal Microbiota Transplant(FMT) Therapy Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 Enterome Bioscience Main Business Overview
11.1.5 Enterome Bioscience Latest Developments
11.2 Rebiotix
11.2.1 Rebiotix Company Information
11.2.2 Rebiotix Faecal Microbiota Transplant(FMT) Therapy Product Offered
11.2.3 Rebiotix Faecal Microbiota Transplant(FMT) Therapy Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 Rebiotix Main Business Overview
11.2.5 Rebiotix Latest Developments
11.3 Ritter Pharmaceuticals
11.3.1 Ritter Pharmaceuticals Company Information
11.3.2 Ritter Pharmaceuticals Faecal Microbiota Transplant(FMT) Therapy Product Offered
11.3.3 Ritter Pharmaceuticals Faecal Microbiota Transplant(FMT) Therapy Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 Ritter Pharmaceuticals Main Business Overview
11.3.5 Ritter Pharmaceuticals Latest Developments
11.4 Finch Therapeutics
11.4.1 Finch Therapeutics Company Information
11.4.2 Finch Therapeutics Faecal Microbiota Transplant(FMT) Therapy Product Offered
11.4.3 Finch Therapeutics Faecal Microbiota Transplant(FMT) Therapy Revenue, Gross Margin and Market Share (2018-2023)
11.4.4 Finch Therapeutics Main Business Overview
11.4.5 Finch Therapeutics Latest Developments
11.5 Crestovo
11.5.1 Crestovo Company Information
11.5.2 Crestovo Faecal Microbiota Transplant(FMT) Therapy Product Offered
11.5.3 Crestovo Faecal Microbiota Transplant(FMT) Therapy Revenue, Gross Margin and Market Share (2018-2023)
11.5.4 Crestovo Main Business Overview
11.5.5 Crestovo Latest Developments
11.6 Maat Pharma
11.6.1 Maat Pharma Company Information
11.6.2 Maat Pharma Faecal Microbiota Transplant(FMT) Therapy Product Offered
11.6.3 Maat Pharma Faecal Microbiota Transplant(FMT) Therapy Revenue, Gross Margin and Market Share (2018-2023)
11.6.4 Maat Pharma Main Business Overview
11.6.5 Maat Pharma Latest Developments
11.7 Seres Therapeutics
11.7.1 Seres Therapeutics Company Information
11.7.2 Seres Therapeutics Faecal Microbiota Transplant(FMT) Therapy Product Offered
11.7.3 Seres Therapeutics Faecal Microbiota Transplant(FMT) Therapy Revenue, Gross Margin and Market Share (2018-2023)
11.7.4 Seres Therapeutics Main Business Overview
11.7.5 Seres Therapeutics Latest Developments
11.8 Second Genome
11.8.1 Second Genome Company Information
11.8.2 Second Genome Faecal Microbiota Transplant(FMT) Therapy Product Offered
11.8.3 Second Genome Faecal Microbiota Transplant(FMT) Therapy Revenue, Gross Margin and Market Share (2018-2023)
11.8.4 Second Genome Main Business Overview
11.8.5 Second Genome Latest Developments
11.9 OpenBiome
11.9.1 OpenBiome Company Information
11.9.2 OpenBiome Faecal Microbiota Transplant(FMT) Therapy Product Offered
11.9.3 OpenBiome Faecal Microbiota Transplant(FMT) Therapy Revenue, Gross Margin and Market Share (2018-2023)
11.9.4 OpenBiome Main Business Overview
11.9.5 OpenBiome Latest Developments
11.10 MicroBiome Therapeutics
11.10.1 MicroBiome Therapeutics Company Information
11.10.2 MicroBiome Therapeutics Faecal Microbiota Transplant(FMT) Therapy Product Offered
11.10.3 MicroBiome Therapeutics Faecal Microbiota Transplant(FMT) Therapy Revenue, Gross Margin and Market Share (2018-2023)
11.10.4 MicroBiome Therapeutics Main Business Overview
11.10.5 MicroBiome Therapeutics Latest Developments
12 Research Findings and Conclusion